In respect to the potential role of STAT3 in enhancing the malignancy of cancer cells [187], this signaling pathway has obtained much attention in triple negative breast cancer (TNBC) therapy and a number of drugs approved by the Food and Drug Administration (FDA) such as niclosamide have been used in treatment of TNBC as inhibitors of STAT3 [188]. The gene discussed is STAT3; the disease is triple-negative breast carcinoma.